MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced a $30 million registered direct offering of ordinary shares. The company will sell 1,734,105 ordinary shares at $17.30 per share to a prominent U.S.-based mutual fund and healthcare-focused investors.
The offering is expected to close around September 30, 2025, with H.C. Wainwright & Co. serving as the exclusive placement agent. The proceeds will support EscharEx's pre-commercial activities, enhance manufacturing capabilities, and fund general corporate purposes. The offering is made through the company's shelf registration statement on Form F-3.
MediWound (Nasdaq: MDWD), leader nel settore dei therapeutic enzimatici per la riparazione dei tessuti, ha annunciato una offerta diretta registrata da 30 milioni di dollari di azioni ordinarie. L'azienda venderà 1.734.105 azioni ordinarie al prezzo di 17,30 dollari per azione a un prominente fondo comune statunitense e a investitori focalizzati sul settore sanitario.
L'offerta dovrebbe chiudersi intorno al 30 settembre 2025, con H.C. Wainwright & Co. come unico agente di collocamento. I proventi sosterranno le attività pre-commerciali di EscharEx, miglioreranno le capacità di produzione e finanzieranno scopi aziendali generali. L'offerta è realizzata tramite la dichiarazione di registrazione su scaffale della società nel Form F-3.
MediWound (Nasdaq: MDWD), líder en terapéuticos enzimáticos para la reparación de tejidos, ha anunciado una oferta directa registrada por 30 millones de dólares de acciones ordinarias. La compañía venderá 1.734.105 acciones ordinarias a 17,30 dólares por acción a un destacado fondo de inversión de EE. UU. y a inversores enfocados en el sector sanitario.
La oferta se espera que cierre alrededor del 30 de septiembre de 2025, con H.C. Wainwright & Co. como asesor exclusivo de colocación. Los ingresos respaldarán las actividades previas a la comercialización de EscharEx, mejorarán las capacidades de fabricación y financiarán fines corporativos generales. La oferta se realiza a través de la declaración de registro de la empresa en el Formulario F-3.
MediWound (Nasdaq: MDWD)는 조직 재생을 위한 효소 치료제 분야의 선두주자로서, 3천만 달러 규모의 등록된 직접 공모로 보통주를 발표했습니다. 회사는 1,734,105주의 보통주를 주당 17.30달러에 미국에 본사를 둔 저명한 뮤추얼 펀드와 의료 분야 투자자들에게 매도합니다.
공모는 2025년 9월 30일경에 마감될 것으로 예상되며, 단독 배정 대리인으로 H.C. Wainwright & Co.가 활동합니다. 조달 자금은 EscharEx의 시판 전 활동을 지원하고, 제조 능력을 강화하며, 일반 기업 목적 자금을 마련하는 데 사용됩니다. 공모는 회사의 Form F-3 선반 등록 명세서를 통해 이루어집니다.
MediWound (Nasdaq: MDWD), leader des thérapeutiques enzymatiques pour la réparation tissulaire, a annoncé une offre publique directe enregistrée de 30 millions de dollars d’actions ordinaires. L’entreprise va vendre 1 734 105 actions ordinaires à 17,30 dollars par action à un fonds commun de placement américain de premier plan et à des investisseurs axés sur les soins de santé.
L’offre devrait être clôturée vers le 30 septembre 2025, avec H.C. Wainwright & Co. en tant que conseiller exclusif en placement. Les fonds permettront de soutenir les activités pré-commercialisation d’EscharEx, d’améliorer les capacités de fabrication et de financer des usages généraux de l’entreprise. L’offre est réalisée via la déclaration d’enregistrement sur étagère de la société au Formulaire F-3.
MediWound (Nasdaq: MDWD), ein führendes Unternehmen im enzymatischen Therapeutika-Bereich für die Gewebe-Reparatur, hat eine registrierte Direktangebot von 30 Millionen Dollar an Stammaktien angekündigt. Das Unternehmen wird 1.734.105 Stammaktien zu 17,30 USD pro Aktie an einen renommierten in den USA ansässigen Investmentfonds und an Investoren aus dem Gesundheitswesen anbieten.
Das Angebot soll voraussichtlich rund 30. September 2025 abgeschlossen werden, wobei H.C. Wainwright & Co. als exklusiver Platzierungsagent fungiert. Die Erlöse unterstützen die vormarktlichen Aktivitäten von EscharEx, verbessern die Fertigungskapazitäten und finanzieren allgemeine Unternehmenszwecke. Das Angebot erfolgt über die Versandregistrierung der Gesellschaft auf dem Form F-3.
MediWound (Nasdaq: MDWD)، الرائد في العلاجات الإنزيمية لإصلاح الأنسجة، أعلن عن عرض مباشر مسجل بقيمة 30 مليون دولار لأسهم عادية. ستبيع الشركة 1,734,105 سهماً عاديًا بسعر 17.30 دولاراً للسهم لمجموعة صناديق استثمارية أمريكية بارزة وليستثمرين مركّزين في قطاع الرعاية الصحية.
يتوقع أن يغلق العرض نحو 30 سبتمبر 2025، فيما تعمل H.C. Wainwright & Co. كوكيل تموضع حصري. ستدعم العائدات نشاط EscharEx قبل التسويق، وتعزز القدرات التصنيعية، وتموّل أغراضاً عامة للشركة. يتم العرض من خلال بيان التسجيل المسبق على النموذج F-3 الخاص بالشركة.
MediWound（纳斯达克股票代码：MDWD），在组织修复用酶治疗领域的领先者，宣布一项直投注册发行的普通股，总额为三千万美元。公司将以每股17.30美元的价格向美国知名的共同基金及聚焦医疗保健的投资者出售1,734,105股普通股。
预计该发行将于2025年9月30日左右完成，H.C. Wainwright & Co.担任独家配售代理。募集资金将用于支持EscharEx的上市前活动、提升制造能力，并用于一般企业用途。该发行是通过公司在Form F-3的货架注册声明进行。
- Secured significant funding of $30 million through registered direct offering
- Investment led by prominent U.S.-based mutual fund and healthcare-focused investors indicates strong institutional interest
- Proceeds will support EscharEx commercialization and manufacturing scale-up
- Share dilution for existing stockholders
- Additional offering expenses and placement agent fees will reduce net proceeds
Insights
MediWound's $30M offering strengthens its financial position for EscharEx commercialization, though diluting existing shareholders by 9%.
MediWound is raising
The pricing of
This financing significantly strengthens MediWound's balance sheet and extends its operational runway. The capital will be critical for the company's transition from clinical-stage to commercial operations for EscharEx, which requires substantial investment in manufacturing infrastructure and pre-commercial activities. The participation of a prominent mutual fund and healthcare-focused investors provides an implicit validation of MediWound's business strategy and product potential in the enzymatic therapeutics market.
However, this offering will dilute existing shareholders by approximately
MediWound Announces
YAVNE, Israel, September 29, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into a definitive securities purchase agreement led by a prominent U.S.-based mutual fund and other healthcare-focused investors for the sale and purchase of 1,734,105 ordinary shares of the Company, par value NIS 0.07 per share, at a purchase price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately
The securities described above are being offered by means of the Company's shelf registration statement on Form F-3 (File No. 333-285908), previously filed with the Securities and Exchange Commission (the "SEC") on March 19, 2025, and declared effective by the SEC on March 27, 2025, the accompanying prospectus, dated March 27, 2025. A final prospectus supplement and accompanying prospectus relating to the securities being offered in the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov. and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these Company securities, nor shall there be any sale of these Company securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
Cautionary Note Regarding Forward-Looking Statements
MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.
Specifically, this press release contains forward-looking statements concerning the registered direct offering, including as to the ability to complete the registered direct offering described above, the expected gross proceeds therefrom, the intended use of proceeds and the timing of the closing of the registered direct offering. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; market and other conditions; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future.
These and other significant factors are discussed in greater detail in MediWound’s annual report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 19, 2025 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound’s current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.
| MediWound Contacts: Hani Luxenburg Chief Financial Officer MediWound Ltd. ir@mediwound.com | Daniel Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com | Media Contact: Ellie Hanson FINN Partners for MediWound ellie.hanson@finnpartners.com +1-929-588-2008 |
FAQ
How much money is MediWound (MDWD) raising in its September 2025 offering?
What is the share price for MediWound's (MDWD) September 2025 offering?
How many shares is MediWound (MDWD) selling in the September 2025 offering?
How will MediWound (MDWD) use the proceeds from the September 2025 offering?
Who are the investors in MediWound's (MDWD) September 2025 offering?
